• Home
  • Category
  • Artificial Intelligence In Drug Discovery Market

Artificial Intelligence In Drug Discovery Market By Technology (Machine Learning, Deep Learning), By Application (Cardiovascular Diseases, Immuno-oncology), By End-User (Contract Research Organizations, Pharmaceutical And Biotechnology Companies), & Region For 2024 -2031

Published Date: August - 2024 | Publisher: MIR | No of Pages: 320 | Industry: latest updates trending Report | Format: Report available in PDF / Excel Format

View Details Buy Now 2890 Download Sample Ask for Discount Request Customization

Artificial Intelligence In Drug Discovery Market Valuation – 2024-2031

The growth of the Artificial Intelligence In Drug Discovery Market, propelled by the increasing adoption of AI and machine learning technologies across the pharmaceutical industry, saw it surpass a valuation of USD 468.59 Million in 2023. Projections indicate a remarkable rise to USD 5539.12 Million by 2031, with a CAGR of 39.90% from 2024 to 2031.

This surge is propelled by the ability of these advanced computational techniques to accelerate the drug discovery pipeline, reduce costs, and improve the success rates of new drug candidates.

Artificial Intelligence In Drug Discovery MarketDefinition/ Overview

Artificial Intelligence In Drug Discovery refers to the application of advanced computational techniques, such as artificial intelligence (AI) and machine learning (ML), in the drug discovery and development processes within the pharmaceutical industry. This innovative approach is revolutionizing the traditional methods of drug discovery by leveraging cutting-edge technologies to accelerate the identification and validation of potential drug candidates, optimize lead compounds, and predict the efficacy, safety, and pharmacokinetic properties of new drugs.

Through the integration of AI and ML algorithms, pharmaceutical companies can analyze vast amounts of data from various sources, including genomic, proteomic, and clinical data. These advanced computational techniques enable virtual screening of massive compound libraries, target identification and validation, lead optimization, and predictive modeling of drug-candidate properties with unprecedented accuracy and efficiency. By harnessing the power of AI and ML, the drug discovery pipeline is streamlined, reducing the time and resources required for drug development while increasing the probability of success in clinical trials.

Artificial Intelligence In Drug Discovery holds the potential to transform the pharmaceutical industry by enabling the rapid exploration of novel drug targets, the design of more effective and safer drug candidates, and the personalization of treatments based on individual genetic profiles. Furthermore, the integration of AI and ML with emerging technologies, such as quantum computing and blockchain, promises to unlock new frontiers in drug discovery, paving the way for more efficient and cost-effective drug development processes, and ultimately benefiting patients and healthcare systems worldwide.

What's inside a
industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Increasing Prevalence of Chronic Diseases and the Need for Novel Therapies Drive the Adoption of AI in Drug Discovery?

Around the world, more and more people are living with long-term health conditions like cancer, heart disease, diabetes, and brain disorders. This is putting a huge strain on healthcare systems and making it clear that we need to find new and better ways to create medicines. The traditional way of developing new drugs has faced many obstacles, such as high costs, long delays, and a high failure rate in clinical trials. But with the help of artificial intelligence (AI) and machine learning (ML), we can find better ways to spot potential targets for new drugs, improve lead compounds, and more accurately predict how well a drug will work, how safe it will be, and how the body will use it.

Imagine a team of AI scientists working tirelessly. They're like detectives, gathering clues from huge piles of information – from genes, proteins, and medical records. These clues help them uncover hidden targets for new drugs and understand how diseases work. They're using super-smart computers and clever programming to sift through this information faster than we could ever imagine. It's like having a superpower – they can quickly zero in on promising drug candidates that are most likely to help us fight specific diseases. With chronic diseases becoming more common, we desperately need better ways to treat them. AI-powered drug discovery is like a beacon of hope, guiding us toward personalized treatments that are tailored to each patient's unique genetic makeup and disease. It's a game-changer that could lead to safer, more effective treatments, faster. AI is breaking down the barriers of traditional drug discovery, opening up new possibilities for treating diseases and improving the lives of patients.

Would the High Computational Costs and Data Management Challenges Hinder the Widespread Adoption of AI in Drug Discovery?

Unlocking the power of AI and ML in drug discovery is not without its hurdles. The hefty computational costs and tricky data management involved can be a real roadblock. Imagine training AI to sift through massive databases of potential drug compounds. That's like a super-computer marathon! It takes a lot of processing power, especially for complex tasks like simulating molecules or predicting outcomes. And we're not just talking about your average laptop here; we're talking special gear like high-performance computers with fancy graphics cards and tensor processing units. These babies don't come cheap! So, for smaller companies and labs with limited budgets, it can be quite a struggle to keep up.

Additionally, the successful implementation of AI in drug discovery relies heavily on the availability of high-quality, diverse, and well-curated datasets. The generation and integration of data from various sources, including genomic, proteomic, structural, and clinical data, present significant challenges in terms of data standardization, quality control, and management. Handling these large and complex datasets requires robust data infrastructures, efficient data processing pipelines, and sophisticated data management strategies.

Challenges in using AI for drug discovery- Data is often not in a consistent format, making it difficult to combine and analyze. - Different data sources don't always work well together, which can limit the effectiveness of AI algorithms. - Protecting data privacy and security, and making sure it follows regulations, makes data management in the pharmaceutical industry even more difficult. To overcome these challenges- Pharmaceutical companies, technology providers, and research institutions need to work together. - Investing in affordable and efficient high-performance computing (HPC) solutions, like cloud computing or shared computing resources, can help reduce the computational burden. - Developing reliable data management platforms, standardized data formats, and advanced data integration techniques can make it easier to manage and analyze data efficiently.

Category-Wise Acumens

How is Machine Learning Revolutionizing Drug Discovery Processes?

Imagine you're developing a new medicine. In the old days, you'd go through thousands of chemicals, testing them one by one to see which ones work best against the disease. Now, there's a faster and smarter waymachine learning. This is a cool technology that's like a super-smart computer program. It learns from data, meaning it can look at all those chemicals at once and figure out which ones have the best chance of fighting the disease. It's like having a digital helper that can speed up the drug discovery process. In the early stages of making a drug, machine learning can help find potential winners by looking at their structure and other features. It can even predict how they'll interact with the body. This means we can rule out the ones that won't work and focus on the ones that have a higher chance of success. It saves time, effort, and money, making the whole process much more efficient.

Machine learning has become a game-changer in drug discovery. It's like giving a super-powered computer a mountain of data on genes, proteins, and medical records. These algorithms then dig through it all to find the weak spots in diseases, which helps scientists design drugs that target those weak spots better. Machine learning also helps in the next stepfiguring out how a drug will behave in the body. It can predict how well it will be absorbed, passed around, changed, and eliminated, so scientists can make sure the drug gets to the right place and does what it's supposed to. But that's not all. Machine learning is also teaming up with other cool technologies like high-speed testing and computer chemistry. Together, they're like a dream team, exploring new possibilities and creating new drugs that could revolutionize the way we treat diseases. It's like having a magic wand that helps scientists design the perfect drug for any illness.

How is AI Transforming Drug Discovery for Cardiovascular Diseases?

Heart disease is a major killer, and finding new ways to treat it is a top priority. Artificial intelligence (AI) is a game-changer in drug discovery for heart disease. It helps researchers understand the disease better, find new targets for drugs, and develop treatments faster. Heart disease covers a lot of different conditions, like heart attacks, heart failure, irregular heartbeats, and strokes. Each of these has its own unique set of causes and risk factors. With AI, researchers can dig into the massive amounts of data from studies on heart disease to find patterns and insights that can lead to new treatments.

Machine learning techniques are being employed to analyze this wealth of data, enabling the identification of novel drug targets associated with specific cardiovascular conditions. By integrating diverse data sources, such as gene expression profiles, protein interaction networks, and clinical trial data, AI algorithms can pinpoint potential therapeutic targets and elucidate their roles in disease pathways, facilitating the development of targeted and personalized treatments.

Hey there! AI is doing some amazing stuff in the world of drug discovery for heart conditions. First off, AI can sift through huge libraries of chemical compounds super fast to find promising candidates that could work as drugs to treat heart problems. This saves scientists a ton of time and effort that they would normally spend testing compounds one by one. But AI doesn't stop there. It can also help scientists design even better drugs. By using machine learning, AI can predict how a drug will behave in the body, which means scientists can tweak it to make it more effective, safer, and easier for the body to absorb. This makes it a lot more likely that the drug will succeed in clinical trials and eventually make it to people who need it.

Gain Access to Artificial Intelligence In Drug Discovery Market Report Methodology

Country/Region-wise Acumens

What factors contribute to North America leading the way in the adoption of AI for drug discovery?

Imagine yourself in the heart of drug discovery, where North America, especially the USA, shines as the reigning champion. Why? It's a melting pot of all the right ingredients. First, we have the big shots of the pharmaceutical world, like Pfizer, Merck, and Johnson & Johnson. They're like the giants of the industry, and they know that AI is the game-changer for finding new drugs. They're pouring money into AI-powered tech and working hand-in-hand with the smartest minds to speed up the process of finding cures. But it's not just the companies. The brains behind this revolution are right here too. From universities like MIT and Harvard to research hubs like Stanford and the Broad Institute, there's a non-stop flow of brilliant people pushing the boundaries of AI in drug discovery. They're the ones making those groundbreaking discoveries that are changing the face of healthcare. So, you see, North America is not just a market for AI in drug discovery. It's the powerhouse where the magic happens, where the sparks of innovation ignite, and where the future of medicine is being shaped.

The region is a powerhouse for cutting-edge computing and infrastructure, which are like the engines that drive the complex calculations and handle the massive data needed to develop new drugs using AI. Companies and research hubs here have access to supercomputers, cloud-based systems, and special hardware that help them crunch through these tasks. The governments in North America, especially in the US, are also pretty cool with AI in healthcare and drug development. They've set up guidelines and frameworks so that companies can use AI responsibly in drug discovery and clinical trials, making sure that new treatments are safe for patients but still pushing innovation. With big pharmaceutical companies, top-notch universities, smart people, plenty of funding, great computing infrastructure, and supportive governments, North America is a magnet for AI-powered drug discovery. And it gets even better because everyone from businesses to researchers to the government are working together to create cutting-edge AI solutions that make developing drugs faster, more precise, and more personalized.

Could Asia Pacific Drive an Increase in Sales within the Artificial Intelligence In Drug Discovery Market?

Hey, did you know Asia is really taking the lead in using AI to find new drugs? Countries like Japan, China, South Korea, and India have big pharma companies that are all about using AI to make drug discovery faster and cheaper. These companies are working with tech experts to create AI-powered drug discovery tools that give them an edge. But that's not all! Asia also has a ton of startups and research centers that are focused on making AI solutions for healthcare and drug development. This means that there's a lot of cool new AI stuff being made just for the pharmaceutical industry. And guess what? Governments in Asia are all for AI. They're giving money and passing laws to make it easier for companies to use AI. They know that AI can help us make healthcare better and the economy stronger.

The region’s rapidly growing population and increasing prevalence of chronic diseases have created a pressing need for new and effective drug therapies. AI-driven drug discovery techniques offer the promise of accelerating the identification and development of novel drug candidates, addressing unmet medical needs, and catering to the region’s healthcare demands.

Hey there! The Asia Pacific region is like a hot spot for drug discovery right now. Lots of companies making medicine are teaming up with tech whizzes and universities. Together, they're sharing cool stuff they've learned, helping each other out, and coming up with fancy new computer models that can help find new drugs faster. But hold up, there are some bumps in the road. Sometimes they don't have enough information, or the rules can be confusing. Plus, it's hard to find people who are really good at both AI and drug discovery. But don't worry, the Asia Pacific region has a huge market, governments are supporting AI, and more and more people are getting good at using it. So, things are looking pretty sweet for the future of drug discovery in this neck of the woods!

Competitive Landscape

The Artificial Intelligence In Drug Discovery Market is characterized by the presence of several established players and innovative solution providers. These companies are continuously pushing the boundaries of AI technology through research and development efforts, strategic partnerships, and the introduction of advanced features and capabilities. The competitive landscape is marked by companies offering a diverse range of AI solutions tailored for various applications across multiple industries.

Some of the prominent players operating in the Artificial Intelligence In Drug Discovery Market include

Accelrys Software Inc., Allergan plc, Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, and Sanofi SA.

Latest Developments

  • In November 2022, Cyclica received a USD 1.8 million grant from the Bill & Melinda Gates Foundation to apply its artificial intelligence-enabled drug discovery platform to discover new non-hormonal contracts, leveraging multiple low-data biological targets.
  • In October 2022, Ginkgo Bioworks, a horizontal platform provider for cell programming, acquired Zymergen. The acquisition is expected to enhance Ginkgo’s platform by integrating strong automation and software capabilities as well as a wealth of experience across diverse biological engineering approaches.
  • In September 2022, CytoReason, an Israel-based biology modeling company, collaborated with Pfizer at the worth of USD 110 million. Pfizer started using CytoReason’s biological models in research to develop new drugs for immune-mediated diseases and cancer immunotherapies.
  • In August 2022, Sanofi partnered with Atomwise in a drug design deal worth USD 1.2 billion. As per the deal, Sanofi paid USD 20 million upfront to leverage the U.S. Company’s AtomNet platform to research small molecules for up to five drug targets.

Report Scope

REPORT ATTRIBUTESDETAILS
STUDY PERIOD

2018-2031

Growth Rate

CAGR of ~39.90% from 2024 to 2031

Base Year for Valuation

2023

HISTORICAL PERIOD

2018-2022

Forecast Period

2024-2031

Quantitative Units

Value in USD Million

Report Coverage

Historical and Forecast Revenue Forecast, Historical and Forecast Volume, Growth Factors, Trends, Competitive Landscape, Key Players, Segmentation Analysis

Segments Covered
  • Technology
  • Application
  • End-user
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Key Players

Accelrys Software Inc., Allergan plc, Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc.

Customization

Report customization along with purchase available upon request

Artificial Intelligence In Drug Discovery Market, By Category

Technology

  • Machine Learning
  • Deep Learning

Application

  • Cardiovascular Diseases
  • Immuno-oncology

End-User

  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies

Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Research Methodology of Market Research

Related Reports

Table of Content

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

List Tables Figures

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

FAQ'S

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@marketinsightsresearch.com

Within 24 to 48 hrs.

You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email